newsfilter
← Latest News
GlobeNewswire·

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S.